LSM3 homolog, U6 small nuclear RNA and mRNA degradation associatedGenealiases: SMX4 · USS2 · YLR438C
Q-omics provides the consensus-scored LSM3 profile across patient tissues and cancer cell-line models. LSM3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LSM3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, LSM3 protein abundance shows 24,652 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KIRC, and PDAC as cancer lineages where LSM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LSM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LSM3 survival associations across molecular data types. LSM3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LSM3 RNA expression–survival associations across cancer types. High LSM3 expression shows unfavorable associations in ACC, KICH, SCLC and LIHC, but favorable associations in UVM and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LSM3 RNA expression.
This table summarizes LSM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LSM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LSM3 shows lower tumor expression in KIRC, KICH, KIRP and THCA and higher tumor expression in LIHC and BRCA. The KIRC box plot shows higher LSM3 RNA expression in normal versus tumor tissue (log2 FC = −0.512, t-test p < 0.001).
This table shows molecular features associated with LSM3 in patient tissues and cancer cell lines. In patient samples, LSM3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, LSM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
